Related Experiment Video
Updated: Aug 5, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Lipid-based nanocarrier-enabled combination therapy for breast cancer: overcoming drug resistance toward precision
Abdul Shadab1, Md Faheem Haider2, Mohammad Abohassan3,4
1Faculty of Pharmacy, Integral University, Lucknow, 226026, India.
Abstract:
Breast cancer continues to be one of the most common causes of cancer death across the globe due to molecular heterogeneity, high rate of recurrence, and growing prevalence of resistance against conventional treatments. Despite the positive contribution of chemotherapy, targeted therapy, and immunotherapy to breast cancer patient outcomes, there is much room for improvement due to the systemic toxicity, low solubility, nonselective biodistribution, and the fast-growing problem of multidrug resistance (MDR) in these approaches. It becomes particularly challenging for triple-negative breast cancer and other aggressive forms of the disease that lack adequate treatment options. As a result, there is an immediate need for developing more effective and specific strategies to address the mentioned obstacles. The idea of combination therapy seems to provide the best rationale for the development of such therapies, as it allows targeting multiple oncogenic signaling pathways, preventing resistance formation, and minimizing the drug dosage used. At the same time, traditional combination therapies usually face issues such as the lack of appropriate pharmacokinetics, instability of combinations, and adverse off-target effects, preventing their effective implementation in clinical practice. One of the ways of solving these problems is through the use of lipid-based nanocarriers that allow combining multiple therapeutic agents and overcoming their drawbacks, such as poor drug solubility, uncontrolled drug release, the absence of tumor selectivity, and susceptibility to efflux. Importantly, lipid nanocarriers may contain several types of drugs, including chemotherapeutic drugs, genetic material, and immunological substances. This paper presents a comprehensive review of recent advances in lipid-based nanocarrier-mediated combination therapies in breast cancer treatment.
Insights
Advanced lipid nanocarriers offer a promising solution for breast cancer combination therapy, overcoming limitations of traditional treatments and addressing multidrug resistance (MDR). These carriers enhance drug delivery and efficacy for aggressive breast cancer forms.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Breast cancer remains a leading cause of cancer death globally, driven by molecular heterogeneity, recurrence, and treatment resistance.
- Conventional therapies like chemotherapy, targeted therapy, and immunotherapy face challenges including systemic toxicity, poor solubility, and multidrug resistance (MDR).
- Aggressive breast cancers, such as triple-negative breast cancer, have limited effective treatment options.
Purpose of the Study:
- To review recent advancements in lipid-based nanocarrier-mediated combination therapies for breast cancer.
- To highlight how nanocarriers can overcome the limitations of traditional combination therapies.
- To explore the potential of nanocarriers in improving drug solubility, tumor selectivity, and overcoming MDR.
Main Methods:
- Comprehensive literature review of recent research on lipid-based nanocarriers in breast cancer therapy.
- Analysis of studies focusing on combination therapy strategies utilizing nanocarriers.
- Examination of nanocarrier properties and their impact on drug delivery and therapeutic outcomes.
Main Results:
- Lipid nanocarriers show potential for combining multiple therapeutic agents (chemotherapeutics, genetic material, immunological substances).
- These nanocarriers can address drawbacks of traditional therapies, including poor solubility, uncontrolled release, lack of tumor selectivity, and efflux pump susceptibility.
- Combination therapy via lipid nanocarriers offers a strategy to target multiple oncogenic pathways, prevent resistance, and minimize drug dosage.
Conclusions:
- Lipid-based nanocarriers represent a significant advancement for breast cancer combination therapy.
- They provide a versatile platform to overcome existing treatment challenges and improve patient outcomes.
- Further research and clinical translation of these nanocarrier systems are warranted for effective breast cancer management.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
07:53Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers